Bolt Bio­ther­a­peu­tics re­vamps as it drops lead can­cer as­set, changes CEO and trims head­count

Bolt Bio­ther­a­peu­tics is reshuf­fling to cut costs and ex­tend its cash run­way to the sec­ond half of 2026.

The Cal­i­for­nia biotech

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.